Results 101 to 110 of about 751,516 (267)
Characterisation of brain D2 dopamine receptors solubilised by lysophosphatidylcholine [PDF]
, 1983 Brain D2 dopamine receptors have been solubilised using lysophosphatidylcholine. The inclusion of proteinase inhibitors during solubilisation enables a preparation to be obtained containing a high proportion of solubilised D2 receptors with ...
Strange, Philip G. +3 more
core +1 more source
Severe Lower Limb and Abdominal Edema Associated with Subcutaneous Apomorphine Infusion
Movement Disorders Clinical Practice, EarlyView.
Guillaume Costentin, David Maltête
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux +26 more
wiley +1 more source
Gut microbiota as a novel therapeutic target for eating disorders and obesity
British Journal of Pharmacology, EarlyView.The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė +5 more
wiley +1 more source
Peripheral targets for neuropathic pain
British Journal of Pharmacology, EarlyView.Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour +3 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov +2 more
wiley +1 more source
The FEBS Journal, EarlyView.We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...
Ersilia Fornetti +11 more
wiley +1 more source
PAIN Reports. Introduction:. The lateral parabrachial nucleus (LPBN), a crucial hub for integrating and modulating diverse sensory information, is known to express both D1 and D2 dopamine receptors and receive dopaminergic inputs.
Ho Koo +4 more
doaj +1 more source
ALTERED EXPRESSION AND FUNCTIONALITY OF A2A ADENOSINE RECEPTORS IN HUNTINGTON’S DISEASE AND OTHER POLYGLUTAMINE DISORDERS [PDF]
, 2009 Several studies have suggested the possible involvement of A2A adenosine receptors in the pathogenesis of neuronal disorders, including Huntington’s disease.
Vincenzi, Fabrizio
core
Journal of Evidence-Based Medicine, EarlyView.ABSTRACT Older patients receiving end‐of‐life palliative care often present with multiple geriatric syndromes, frailty, and comorbid symptom burden, resulting in a high risk of medication‐related harm. This guideline focuses on pharmacological management of distressing symptoms in older patients receiving end‐of‐life or hospice‐oriented palliative care,
Daiping Li +7 more
wiley +1 more source